Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has granted stock options to four new employees under its 2022 Inducement Plan. The grants total 124,000 shares with an exercise price of $6.47 per share.
The stock options feature a 4-year vesting schedule with 25% vesting after the first year and the remaining portion vesting monthly over three years. The options have a 10-year term and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA), azienda biofarmaceutica in fase clinica specializzata in terapie mirate per il cancro al seno, ha assegnato opzioni su azioni a quattro nuovi dipendenti nell'ambito del suo Inducement Plan 2022. Le assegnazioni ammontano a un totale di 124.000 azioni con un prezzo di esercizio di $6,47 per azione.
Le opzioni prevedono un vestizione in 4 anni, con il 25% che matura dopo il primo anno e il resto che matura mensilmente nei tre anni successivi. Le opzioni hanno una durata di 10 anni e sono state concesse in conformità alla Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA), una empresa biofarmacéutica en fase clínica centrada en terapias dirigidas para el cáncer de mama, ha otorgado opciones sobre acciones a cuatro nuevos empleados bajo su Inducement Plan 2022. Las concesiones suman un total de 124.000 acciones con un precio de ejercicio de $6,47 por acción.
Las opciones cuentan con un programa de adquisición de derechos de 4 años, con un 25% que se adquiere tras el primer año y el resto que se adquiere mensualmente durante los tres años siguientes. Las opciones tienen un plazo de 10 años y se concedieron de conformidad con la Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA), 유방암 표적 치료에 주력하는 임상 단계의 바이오제약회사, 은 2022년 유인 계획(Inducement Plan)에 따라 신규 직원 4명에게 스톡옵션을 부여했습니다. 총 부여 수량은 124,000주이며 행사 가격은 주당 $6.47입니다.
스톡옵션은 4년 베스팅 일정을 따르며, 첫 해 종료 시 25%가 베스트되고 나머지는 향후 3년 동안 매달 베스팅됩니다. 옵션의 유효 기간은 10년이며 Nasdaq Listing Rule 5635(c)(4)에 따라 부여되었습니다.
Olema Oncology (Nasdaq: OLMA), une société biopharmaceutique en phase clinique spécialisée dans les thérapies ciblées pour le cancer du sein, a accordé des options d'achat d'actions à quatre nouveaux employés dans le cadre de son Inducement Plan 2022. Les attributions totalisent 124 000 actions avec un prix d'exercice de 6,47 $ par action.
Les options comportent un calendrier d'acquisition sur 4 ans, avec 25 % acquis après la première année et le solde acquis mensuellement sur les trois années suivantes. Les options ont une durée de 10 ans et ont été accordées conformément à la Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Schwerpunkt auf zielgerichteten Therapien gegen Brustkrebs, hat unter seinem Inducement Plan 2022 Aktienoptionen an vier neue Mitarbeiter gewährt. Die Zuteilungen belaufen sich insgesamt auf 124.000 Aktien zu einem Ausübungspreis von $6,47 pro Aktie.
Die Optionen unterliegen einem Vesting-Zeitraum von 4 Jahren, wobei 25 % nach dem ersten Jahr vesten und der Rest über die folgenden drei Jahre monatlich vestet. Die Optionen haben eine Laufzeit von 10 Jahren und wurden gemäß der Nasdaq Listing Rule 5635(c)(4) gewährt.
- None.
- None.
SAN FRANCISCO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 124,000 shares of the Company's common stock, effective as of September 2, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
What stock options did Olema Oncology (OLMA) grant to new employees in September 2025?
What is the vesting schedule for Olema Oncology's (OLMA) September 2025 employee stock options?
What is the exercise price for Olema Oncology's (OLMA) September 2025 inducement grants?
Under which plan were Olema Oncology's (OLMA) September 2025 stock options granted?
